大麻二酚与Δ9-四氢大麻酚对驾驶表现的影响:一项随机临床试验
该双盲、参与者内随机临床试验在荷兰马斯特里赫特大学进行,纳入26名健康偶发性大麻使用者,比较吸入含THC和CBD的大麻后驾驶表现。主要终点为100公里道路驾驶中的车道位置标准差(SDLP)。结果显示,吸入后40-100分钟,THC主导型和THC/CBD等量型大麻显著增加SDLP,而CBD主导型与安慰剂无显著差异;240-300分钟时各条件间无显著差异。
要点
- 吸入THC主导或THC/CBD等量大麻后40-100分钟驾驶损害显著增加。
- CBD主导大麻在40-100分钟和240-300分钟均未显著增加SDLP。
- THC及THC/CBD的驾驶损害在240-300分钟时不再显著。
核心结论
- 吸入THC主导型和THC/CBD等量型大麻后40-100分钟SDLP较安慰剂显著增加,但240-300分钟无显著差异;CBD主导型与安慰剂无显著差异。
研究设计与样本
- 双盲、参与者内随机临床试验,在荷兰马斯特里赫特大学心理学与神经科学学院进行,纳入26名健康偶发性大麻使用者。
- 参与者随机吸入THC主导型、CBD主导型、THC/CBD等量型和安慰剂大麻,THC和CBD剂量均为13.75 mg。
- 主要终点为100公里道路驾驶测试中的车道位置标准差(SDLP),测试在吸入后40分钟和240分钟开始。
主要发现
- 吸入后40-100分钟,SDLP在CBD主导型为18.21 cm,THC主导型为20.59 cm,THC/CBD等量型为21.09 cm,安慰剂为18.28 cm。
- 与安慰剂相比,THC主导型SDLP增加2.33 cm(95% CI 0.80-3.86;P < .001),THC/CBD等量型增加2.83 cm(95% CI 1.28-4.39;P < .001),CBD主导型变化-0.05 cm(95% CI -1.49-1.39;P > .99)。
- 吸入后240-300分钟,SDLP在CBD主导型为19.03 cm,THC主导型为19.88 cm,THC/CBD等量型为20.59 cm,安慰剂为19.37 cm,各组与安慰剂相比均无显著差异。
- 188次测试驾驶中,16次(8.5%)因安全考虑终止。
关键数值与推荐
- 在校准血液酒精浓度(BAC)0.02%时,SDLP较安慰剂增加1.12 cm;BAC 0.05%时增加2.4 cm。
临床怎么用
- 提示含THC的大麻在吸入后早期可能损害驾驶能力,临床咨询应告知患者相关风险。
- CBD主导型大麻未显示显著驾驶损害,但效应量可能未排除临床重要损害,且测试剂量未必代表常见使用情况。
局限性
- CBD主导型大麻的效应量可能未排除临床重要损害。
- 测试剂量可能不代表常见使用情况。
- 样本量为26名健康偶发性使用者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cannabis use has been associated with increased crash risk, but the effect of cannabidiol (CBD) on driving is unclear. OBJECTIVE: To determine the driving impairment caused by vaporized cannabis containing Δ9-tetrahydrocannabinol (THC) and CBD. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, within-participants, randomized clinical trial was conducted at the Faculty of Psychology and Neuroscience at Maastricht University in the Netherlands between May 20, 2019, and March 27, 2020. Participants (N = 26) were healthy occasional users of cannabis. INTERVENTIONS: Participants vaporized THC-dominant, CBD-dominant, THC/CBD-equivalent, and placebo cannabis. THC and CBD doses were 13.75 mg. Order of conditions was randomized and balanced. MAIN OUTCOMES AND MEASURES: The primary end point was standard deviation of lateral position (SDLP; a measure of lane weaving) during 100 km, on-road driving tests that commenced at 40 minutes and 240 minutes after cannabis consumption. At a calibrated blood alcohol concentration (BAC) of 0.02%, SDLP was increased relative to placebo by 1.12 cm, and at a calibrated BAC of 0.05%, SDLP was increased relative to placebo by 2.4 cm. RESULTS: Among 26 randomized participants (mean [SD] age, 23.2 [2.6] years; 16 women), 22 (85%) completed all 8 driving tests. At 40 to 100 minutes following consumption, the SDLP was 18.21 cm with CBD-dominant cannabis, 20.59 cm with THC-dominant cannabis, 21.09 cm with THC/CBD-equivalent cannabis, and 18.28 cm with placebo cannabis. SDLP was significantly increased by THC-dominant cannabis (+2.33 cm [95% CI, 0.80 to 3.86]; P < .001) and THC/CBD-equivalent cannabis (+2.83 cm [95% CI, 1.28 to 4.39]; P < .001) but not CBD-dominant cannabis (-0.05 cm [95% CI, -1.49 to 1.39]; P > .99), relative to placebo. At 240 to 300 minutes following consumption, the SDLP was 19.03 cm with CBD-dominant cannabis, 19.88 cm with THC-dominant cannabis, 20.59 cm with THC/CBD-equivalent cannabis, and 19.37 cm with placebo cannabis. The SDLP did not differ significantly in the CBD (-0.34 cm [95% CI, -1.77 to 1.10]; P > .99), THC (0.51 cm [95% CI, -1.01 to 2.02]; P > .99) or THC/CBD (1.22 cm [95% CI, -0.29 to 2.72]; P = .20) conditions, relative to placebo. Out of 188 test drives, 16 (8.5%) were terminated due to safety concerns. CONCLUSIONS AND RELEVANCE: In a crossover clinical trial that assessed driving performance during on-road driving tests, the SDLP following vaporized THC-dominant and THC/CBD-equivalent cannabis compared with placebo was significantly greater at 40 to 100 minutes but not 240 to 300 minutes after vaporization; there were no significant differences between CBD-dominant cannabis and placebo. However, the effect size for CBD-dominant cannabis may not have excluded clinically important impairment, and the doses tested may not represent common usage. TRIAL REGISTRATION: EU Clinical Trials Register: 2018-003945-40.
引用
- Arkell TR, Vinckenbosch F, Kevin RC, et al. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020. PMID: 33258890. doi:10.1001/jama.2020.21218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。